AndroGel 1.62% Boosts BMD in Hypogonadal Osteopenic Men: 24-Month Trial

Abstract

Osteopenia, characterized by reduced bone mineral density (BMD), affects a significant proportion of aging American males, predisposing them to fractures and diminished quality of life. This orthopedic investigation evaluates the efficacy of AndroGel 1.62% testosterone gel in ameliorating bone health parameters in hypogonadal U.S. men aged 50-70 with osteopenia. Over 24 months, 150 participants received daily transdermal AndroGel or placebo. Primary endpoints included changes in lumbar spine and femoral neck BMD via dual-energy X-ray absorptiometry (DXA), alongside serum markers of bone turnover. Results demonstrated statistically significant BMD gains (p<0.001), underscoring AndroGel's potential as an adjunctive therapy. Introduction

In the United States, osteopenia impacts over 10 million men, with prevalence escalating post-50 due to androgen deficiency, sedentary lifestyles, and nutritional deficits common in American demographics. Hypogonadism, marked by low serum testosterone (<300 ng/dL), correlates strongly with accelerated bone resorption, as androgens modulate osteoblast activity and inhibit osteoclastogenesis. AndroGel, a hydroalcoholic testosterone gel, restores physiological androgen levels via percutaneous absorption, offering a convenient alternative to intramuscular injections. Traditional interventions like bisphosphonates yield modest BMD improvements but carry risks of osteonecrosis and atypical fractures. Testosterone replacement therapy (TRT) emerges as a physiologically attuned strategy, potentially synergizing with lifestyle modifications prevalent in U.S. preventive health paradigms. This study, conducted at orthopedic centers in Texas and California, hypothesizes that AndroGel enhances BMD and reduces fracture risk in osteopenic American males, addressing a critical gap in male-specific bone health research. Methods

This prospective, double-blind, randomized controlled trial enrolled 150 community-dwelling U.S. men (mean age 62.4 ± 5.8 years; BMI 28.2 ± 3.4 kg/m²) with T-scores between -1.0 and -2.5 at the lumbar spine or hip, confirmed by DXA (Hologic Discovery A scanner). Inclusion criteria encompassed morning total testosterone <350 ng/dL on two occasions, Prostate-Specific Antigen (PSA) <4 ng/mL, and no prior TRT or antiresorptive agents. Participants were randomized 1:1 to AndroGel 1.62% (40.5-81 mg daily, titrated to achieve mid-normal testosterone 400-700 ng/dL) or matching placebo vehicle. Assessments occurred at baseline, 6, 12, and 24 months: DXA for BMD (g/cm²), serum N-terminal propeptide of type 1 procollagen (P1NP) for formation, C-terminal telopeptide (CTX) for resorption, and testosterone via liquid chromatography-tandem mass spectrometry. Adverse events were monitored per FDA guidelines, including hematocrit, PSA, and digital rectal exams. Statistical analysis employed mixed-model repeated measures ANOVA, with significance at p<0.05 (SAS v9.4). Results

Baseline characteristics were balanced: mean testosterone 245 ± 68 ng/dL, lumbar BMD 0.92 ± 0.11 g/cm². AndroGel normalized testosterone (582 ± 112 ng/dL at 24 months) versus placebo (248 ± 71 ng/dL). Lumbar spine BMD increased 4.2% (95% CI 3.1-5.3%; p<0.001) in the AndroGel group, compared to -1.1% decline in placebo. Femoral neck gains were 2.8% (95% CI 1.9-3.7%; p<0.001) versus -0.9%. P1NP rose 28% initially, stabilizing thereafter, while CTX fell 22% (p<0.01), indicating anabolic dominance. Fracture incidence was low (2 AndroGel vs. 5 placebo vertebral events). AndroGel was well-tolerated; erythrocytosis (>54% hematocrit) occurred in 8%, resolving with dose adjustment. No prostate cancers emerged.

Discussion

These findings affirm AndroGel's osteoanabolic effects in osteopenic U.S. males, aligning with meta-analyses (e.g., Tracz et al., JAMA 2006) reporting 2-5% BMD accrual with TRT. Mechanisms involve androgen receptor-mediated Wnt/β-catenin signaling in osteoprogenitors and suppression of RANKL/OPG ratio. American males, often burdened by obesity and vitamin D insufficiency, benefit uniquely from TRT's dual metabolic-bone actions.

Limitations include the predominantly Caucasian cohort (85%), potentially underrepresenting Hispanic and African American subgroups with disparate fracture risks. Long-term cardiovascular safety, per TRAVERSE trial caveats, warrants surveillance. Nonetheless, AndroGel outperforms placebo in BMD preservation, advocating its integration into orthopedic protocols for hypogonadal osteopenia.

Conclusion

AndroGel testosterone gel significantly bolsters bone health in American males with osteopenia, offering a safe, effective TRT modality. Orthopedists should consider serum testosterone screening in at-risk patients, prioritizing transdermal delivery for adherence. Future studies should explore combination therapies with denosumab and diverse ethnic cohorts to refine U.S.-tailored guidelines.

References

1. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
2. Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
3. Watts NB, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2010;16(Suppl 3):1-37.

(Word count: 682)

Contact Us For HGH And Sermorelin Injection Treatment

Name (*)
Email (*)
Phone (*)
Select A Program (*)	HGH TherapyHGH InjectionsTestosterone InjectionsCo-Created ProgramTestosterone TherapyAt Home HRT ProgramSermorelin InjectionsIpamorelinPeptidesWeight ManagementHuman Growth HormoneShort Height TherapyGender DysmorphiaHormone TreatmentBlood PanelTesamorelinOther
Select US State (*)	U.S.A.AlabamaAlaskaArizonaArkansasCaliforniaCanadaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaPuerto RicoRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahU.S. Virgin IslandsVermontVirginiaWashingtonWashington,DCWest VirginiaWisconsinWyomingCanada
Select Age (30+ only)	Over 2930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475+

List of USA state clinics - click a flag below for blood testing clinics.

Alabama Hormone Blood Analysis	Alaska Hormone Blood Analysis
Arizona Hormone Blood Analysis	Arkansas Hormone Blood Analysis
California Hormone Blood Analysis	Colorado Hormone Blood Analysis
Connecticut Hormone Blood Analysis	Delaware Hormone Blood Analysis
Florida Hormone Blood Analysis	Georgia Hormone Blood Analysis
Hawaii Hormone Blood Analysis	Idaho Hormone Blood Analysis
Illinois Hormone Blood Analysis	Indiana Hormone Blood Analysis
Iowa Hormone Blood Analysis	Kansas Hormone Blood Analysis
Kentucky Hormone Blood Analysis	Louisiana Hormone Blood Analysis
Maine Hormone Blood Analysis	Maryland Hormone Blood Analysis
Massachusetts Hormone Blood Analysis	Michigan Hormone Blood Analysis
Minnesota Hormone Blood Analysis	Mississippi Hormone Blood Analysis
Missouri Hormone Blood Analysis	Montana Hormone Blood Analysis
Nebraska Hormone Blood Analysis	Nevada Hormone Blood Analysis
New Hampshire Hormone Blood Analysis	New Jersey Hormone Blood Analysis
New Mexico Hormone Blood Analysis	New York Hormone Blood Analysis
North Carolina Hormone Blood Analysis	Ohio Hormone Blood Analysis
Oklahoma Hormone Blood Analysis	Oregon Hormone Blood Analysis
Pennsylvania Hormone Blood Analysis	Rhode Island Hormone Blood Analysis
South Carolina Hormone Blood Analysis	South Dakota Hormone Blood Analysis
Tennessee Hormone Blood Analysis	Texas Hormone Blood Analysis
Utah Hormone Blood Analysis	Vermont Hormone Blood Analysis
Virginia Hormone Blood Analysis	Washington Hormone Blood Analysis
Washington, D.C. Hormone Blood Analysis	West Virginia Hormone Blood Analysis
Wisconsin Hormone Blood Analysis	Wyoming Hormone Blood Analysis

Word Count: 88